Generic Injectables Market 2024-2033 : Demand, Trend, Segmentation, Forecast, Overview And Top Companies

The Generic Injectables Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Generic Injectables Market:

https://www.thebusinessresearchcompany.com/report/generic-injectables-global-market-report

According to The Business Research Company’s Generic Injectables Global Market Report 2024, The generic injectables market size has grown rapidly in recent years. It will grow from $109.42 billion in 2023 to $125.97 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to cost-effectiveness, patent expirations, healthcare access initiatives, market competition, global pharmaceutical trends..

The generic injectables market size is expected to see rapid growth in the next few years. It will grow to $209.47 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to increasing aging population, strategic alliances, regulatory changes, rising healthcare awareness, market innovation.. Major trends in the forecast period include focus on quality and regulatory compliance, adoption of the 505(b)(2) regulatory pathway, development of novel drug delivery technologies, collaborations and partnerships in the industry, increased focus on specialty injectable therapies..

The rising prevalence of cancer and cardiovascular diseases is expected to propel the growth of the generic injectable market going forward. Cardiovascular diseases refer to a group of disorders of the heart and blood vessels, and cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. Generic injectables are used in cancer and cardiac diseases to offer similar pharmaceutical equivalence or bioequivalence to brand-drugs and enhanced drug availability and accessibility to provide more affordable treatment. For instance, in September 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by noncommunicable diseases (NCDs) or chronic diseases every year globally were 17.9 million deaths are from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths are from diabetes. Therefore, the rising prevalence of cancer and cardiovascular diseases is driving the growth of the generic injectable market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10776&type=smp

The generic injectables market covered in this report is segmented –

1) By Product Type: Monoclonal Antibodies, Cytokines, Insulin, Vaccines, Other Products

2) By Container Type: Vials, Ampoules, Premix, Prefilled Syringes, Other Containers

3) By Route Of Administration: Intravenous, Intramuscular, Subcutaneous, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Prescription Stores

5) By Application: Oncology, Diabetes , Infectious Diseases , Blood Disorders , Musculoskeletal Disorders , Hormonal Disorders , Pain Management , CNS Diseases , Cardiovascular Diseases

Product innovations are a key trend gaining popularity in the generic injectables market. Major companies operating in the generic injectables market are advancing generic injectables to sustain their position in the market. For instance, in April 2022, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched Treprostinil Injection in the U.S. market. This drug is a therapeutic equivalent generic version of Remodulin (treprostinil) Injection approved by the U. S. Food and Drug Administration (USFDA), a US-based agency. This drug is applicable for patients requiring a transition from epoprostenol to reduce the rate of clinical deterioration.

The generic injectables market report table of contents includes: